Skip to content

Comparing the outcomes and side effects of adjuvant chemotherapy with and without ginger in ovarian cancer patients

Comparing the outcomes and side effects of adjuvant chemotherapy with and without ginger in ovarian cancer patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014031510901N4
Enrollment
90
Registered
2014-04-09
Start date
2014-04-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer. Malignant neoplasm of ovary

Interventions

Intervention 1: Control group: Karbo platinum dose Taksl Pakly 5-6 AUC and dose of 175 mg per square meter for 6 cycles. Intervention 2: Groups: drug Karbv platinum dose 5-6 AUC and Pakly Taksl dose o
Treatment - Drugs
Control group: Karbo platinum dose Taksl Pakly 5-6 AUC and dose of 175 mg per square meter for 6 cycles
Groups: drug Karbv platinum dose 5-6 AUC and Pakly Taksl dose of 175 mg per square meter and ginger (ginger 1 g made at the that Faculty of Pharmacy, Tabriz) at a dose of 2 g daily for 6 cycles admin

Sponsors

vice chancellor of research,Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Encloses Criteria: women with ovarian cancer who had cytoreductive surgery; Wilting to participate in study Exclusion criteria: Sensitivity to ginger ; history of previous chemotherapy; history of gynecological cancer; using vit E or omega3; Intolerances to chemotherapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The results of the CT scan of the abdomen and pelvis. Timepoint: Intervals during treatment and after treatment every 3 months for one year. Method of measurement: CT scan of the abdomen and pelvis.;CA125 results in the groups receiving platinum and paclitaxel. Timepoint: Intervals during treatment and after treatment every 3 months for one year. Method of measurement: Blood tests.;Side effects. Timepoint: During treatment. Method of measurement: Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Parvin Mostafa Gharabaghi

Tabriz University of Medical Sciences

wrhrcenter@gmail.com; Gharabagh.p@tbzmed.ac.ir; lahrodi59@yahoo.com+98 41155

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026